Categories
News

Pfizer Sells $1 Billion Bond Funding Vaccine Production – Bloomberg

Proceeds from the sale are marked for research and development expenses and the manufacturing and distribution of Covid-19 vaccines. The New York-based pharmaceutical company sees the vaccine bringing in $33.5 billion of revenue this year, which would make it one of the top-selling medicines ever.

http://archive.today/2021.09.06-162254/https://www.bloomberg.com/news/articles/2021-08-16/pfizer-to-sell-sustainability-bond-funding-vaccine-production

Categories
News

With IFFIm, donors have an immediate impact – IFFIm

IFFIm’s financial base consists of grants from 10 sovereign sponsors. By signing the grant agreements, countries agree to pay these obligations in a specified schedule of payments.

CountryUS$ equivalentCurrency of pledge
United KingdomUS$ 3,652 million over 23 yearsGBP 2,130 million
France FranceUS$ 1,884 million over 20 yearsEUR 1,390 million
ItalyUS$ 821 million over 25 yearsEUR 654 million* *Includes a pledge to support the Coalition for Epidemic Preparedness Innovations (CEPI) through Gavi for the development of COVID-19 vaccine candidates.  
Norway NorwayUS$ 647 million over 25 yearsUS$ 27 million & NOK 5,100 million* *Includes additional pledges to support the Coalition for Epidemic Preparedness Innovations (CEPI) through Gavi for the development of COVID-19 vaccine candidates
The Netherlands The NetherlandsUS$ 487 million over 20 yearsEUR 330 million & US$ 67 million
AustraliaUS$ 284 million over 20 yearsAUD 288 million
Spain SpainUS$ 240 million over 20 yearsEUR 190 million
Sweden SwedenUS$ 38 million over 15 yearsSEK 276 million
South AfricaUS$ 20 million over 20 yearsUS$ 20 million
Brazil BrazilUS$ 20 million over 20 yearsUS$ 20 million
TOTALUS$ 8 billion (approximately) 

http://archive.today/2021.05.28-164114/https://iffim.org/donors

Categories
Publications

Social bonds in response to the Covid-19 crisis: when financial markets save lives

Social bonds are an attractive investment for worldwide institutional and individual investors looking for a socially responsible investment with a clear, unambiguous purpose and a portfolio diversification opportunity with attractive risk-adjusted returns. Although the social bond market has been growing fast, it has so far remained a niche sector.

…Over the last few weeks, several social Covid-19 bonds have already been issued by a number of multilateral institutions and public agencies and are already generating significant investor interest, paving the way for more issuances. The stage is now set for social bonds to move from a niche solution to a mainstream one.

http://archive.today/2021.09.06-173555/https://www.ecmi.eu/sites/default/files/when_financial_markets_save_lives_ecmi_commentary.pdf

Categories
News

Analysis: Vaccine bond sales to soar to fund COVID-19 shots for poor countries – Reuters

Socially conscious bond investors will be targeted in a coming wave of vaccine bond deals that will seek to provide billions of dollars for the speedy rollout of COVID-19 shots for developing countries.

http://archive.today/2021.09.06-150913/https://www.reuters.com/article/health-coronavirus-vaccine-bonds-idINKBN28W0M9

Categories
News

The Case for a Coronavirus-Vaccine Bond – The New Yorker

Drugs are a risky business and, for equity investors hoping to eventually share in the profits, each stage of development presents an escalated risk. Lo reasoned that substantially lowering the risks, even if it meant correspondingly lowering the rewards, could attract investment instead from ordinary bond markets—that is, from managers of pension funds, university endowments, and sovereign-wealth funds, who control a great deal of money and generally invest in low-risk, low-return assets. 

Given how uncertain vaccine markets are, the paper notes, governments (“public-sector interventions,” and so forth), would need to guarantee a vaccine bond by committing in advance to purchase and stockpile vaccines. The paper’s most creative suggestion is for a subscription model, a kind of vaccine Netflix, where governments would pay an annual fee to a new international-development fund, one that could perhaps be managed by the G7. The fund could float a bond to both advance vaccine biotechs and to make market commitments to Big Pharma. The virus, the markets, and the science are global.

…it would be much better for the government to say that the money is not from taxpayers. “We’re borrowing it from the rest of the world. And if and when you succeed, or any of the other hundred and fifty projects—that could have been funded, but aren’t being funded right now—succeeds, all the bond holders will get paid. That would be great. Everybody earns a return.”

http://archive.today/2020.08.15-143205/https://www.newyorker.com/news/daily-comment/the-case-for-a-coronavirus-vaccine-bond